|
2025 Conference Publication Australian patients with IDH<sub>1 </sub>mutatedcholangiocarcinoma treated with ivosidenib: initial resultsfrom the phase 3b ProvIDHe studyPrice, Tim, Sim, Hao-Wen, Eastgate, Melissa, Mclachlan, Sue-Anne, Dean, Andrew, George, David, Weeratunge, Roshi, Zhang, Yoz and Oo, Maung Maung (2025). Australian patients with IDH1 mutatedcholangiocarcinoma treated with ivosidenib: initial resultsfrom the phase 3b ProvIDHe study. HOBOKEN: WILEY. |
|
2025 Conference Publication Retrospective cohort study of Treatment Patterns and Outcomes for Patients with locally advanced Rectal Cancer across Three Metropolitan Hospitals in BrisbaneMacilwraith, Philip, Turner, Cassie, Roberts, Kate, Bigby, Kieron, Kang, Sebastian, Wyld, David, Burge, Matthew and Eastgate, Melissa (2025). Retrospective cohort study of Treatment Patterns and Outcomes for Patients with locally advanced Rectal Cancer across Three Metropolitan Hospitals in Brisbane. HOBOKEN: WILEY. |
|
2025 Conference Publication Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) plus bevacizumab (B) plus transarterial chemoembolization (TACE) and placebos plus TACE: EMERALD-1 post hoc analysisRoderburg, C., Sangro, B., Bouattour, M., Park, J. -W., Romero, M. Del Consuelo Diaz, Erinjeri, J. P., Alves, G., Gu, S., Manikhas, A., Kuroda, H., Suksombooncharoen, T., Vo, T. Hoi Trung, Ostwal, V. S., Eastgate, M., Vaccaro, G., Griffin, R., Ali, S., Balaji, K. and Chan, S. L. (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) plus bevacizumab (B) plus transarterial chemoembolization (TACE) and placebos plus TACE: EMERALD-1 post hoc analysis. BASEL: KARGER. |
|
2025 Conference Publication Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+transarterial chemoembolization (TACE) and placebos+TACE: EMERALD-1 post hoc analysisRoderburg, C., Sangro, B., Bouattour, M., Park, J-W., del Consuelo Díaz Romero, M., Erinjeri, J. P., Alves, G., Gu, S., Manikhas, A., Kuroda, H., Suksombooncharoen, T., Hoi Trung Vo, T., Ostwal, V. S., Eastgate, M., Vaccaro, G., Griffin, R., Ali, S., Balaji, K. and Chan, S. L. (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+transarterial chemoembolization (TACE) and placebos+TACE: EMERALD-1 post hoc analysis. Annual conference of the German Society of Gastroenterology, and Digestive and Metabolic Diseases with Endoscopy Section (DGVS) Viszeralmedizin 2025, Leipzig, Germany, 15–20 September 2025. Stuttgart, Germany: Georg Thieme. doi: 10.1055/s-0045-1810980 |
|
2025 Conference Publication Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysisSangro, Bruno, Bouattour, Mohamed, Park, Joong-Won, Diaz, Dr. Consuelo, Erinjeri, Joseph P., Alves, Gustavo Vasconcelos, Gu, Shan-Zhi, Manikhas, Aleksei, Kuroda, Hidekatsu, Suksombooncharoen, Thatthan, Vo, Truc Hoi Trung, Ostwal, Vikas S., Eastgate, Melissa A., Vaccaro, Gina M., Griffin, Rebecca, Ali, Sajid, Balaji, Kavitha and Chan, Stephen Lam (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis. 2025 ASCO Gastrointestinal (GI) Cancers Symposium, San Francisco, CA United States, 23 - 25 January 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.4_suppl.574 |
|
2024 Conference Publication Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe studySim, H-W., McLachlan, S-A., Dean, A., Price, T.J., Eastgate, M., Rimassa, L., Mercade, T. Macarulla, Malka, D., Gharbi, H., Robert, R., Sullivan, A. and Vogel, A. (2024). Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study. ESMO Asia Congress 2024, Singapore, 6 – 8 December 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.10.171 |
|
2024 Conference Publication "Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer"Beesley, Vanessa L., Roset, Natalie, Turner, Jane, Yates, Patsy, Wyld, David, Eastgate, Melissa, Chan, Raymond, Collins, Louisa, Stewart, Michelle, Beebe, Hanna, Malt, Maryrose, Kelly, Caroline and Neale, Rachel (2024). "Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer". COSA's 51st Annual Scientific Meeting: Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116 |
|
2024 Conference Publication Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trialNalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121 |
|
2023 Conference Publication Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEODay, Fiona, Sridharan, Swetha, Michael, Michael, Christophersen, Louise, Moore, Melissa M., Eastgate, Melissa A., Thompson, Stephen, MWEEMPWA, ANGELA, Oldmeadow, Christopher, Fraser, Allison and Martin, Jarad (2023). Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEO. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps4172 |
|
2023 Conference Publication CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanomaLau, Peter Kar Han, Harris, Samuel John, Eastgate, Melissa A., Kee, Damien, Mant, Andrew, Nott, Louise M., Gedye, Craig, Inderjeeth, Andrisha Jade, Underhill, Craig, Weppler, Alison Margaret, Wallace, Roslyn, Lee, Belinda, Au-Yeung, George, Williams, Narelle, Ariza Ospino, Daniel, Gonzales, Louise, Shackleton, Mark J., Lo, Serigne N., McArthur, Grant A. and Sandhu, Shahneen (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.9525 |
|
2022 Conference Publication Adjuvant therapy in resected melanoma: Experience from royal brisbane and women's hospitalTurner, Cassie L. and Eastgate, Melissa (2022). Adjuvant therapy in resected melanoma: Experience from royal brisbane and women's hospital. HOBOKEN: WILEY. |
|
2022 Conference Publication A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitorsKhushalani, N.I., Shue, H., Gedye, C., Mazumder, A., Sharma, S., Eastgate, M., Majem Tarruella, M., Antonanzas Basa, M., Montaudie, H., Marais-Nieman, R., de la Cruz Merino, L., Clements, A., Mortier, L., Jameson, M., Shojaei, F., Ning, J., Aiyer, L., Gillings, M., Kabbinavar, F. and Ascierto, P. (2022). A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors. ESMO Asia Congress 2022, Singapore, 2-4 December 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.10.052 |
|
2022 Conference Publication Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian settingKim, Hansoo, Kulasegaran, Tivya, Eastgate, Melissa, Wyld, David, Burge, Matthew and Nalder, Mark (2022). Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting. HOBOKEN: WILEY. |
|
2022 Conference Publication Tumour naive circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trialDay, D., Starus, A., Lamik, A., Sieber, O., Begbie, S., Bonaventura, A., Rai, S., Karanth, N., Underhill, C. R., Nott, L. M., Van Hazel, G., Van Hagen, T., Wong, M., Saqib, A., Eastgate, M., Srivastav, R., Chia, J., Toh, H. C., Jones, F. and Segelov, E. (2022). Tumour naive circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Electr Network, Sep 09-13, 2022. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2022.07.518 |
|
2022 Conference Publication Toxicity and response to ipilimumab and nivolumab in elderly patients with metastatic melanoma: A multicenter retrospective analysisPathmanathan, Shivanshan, Babu, Hari S., Dzienis, Marcin Radoslaw, Azer, Mary and Eastgate, Melissa A. (2022). Toxicity and response to ipilimumab and nivolumab in elderly patients with metastatic melanoma: A multicenter retrospective analysis. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2020 Conference Publication Psychosocial impacts of COVID-19 on oncology workforces: metro versus regional AustraliaAhern, Elizabeth Stephanie, Gasper, Harry Michael, Chan, Bryan, Roberts, Natasha Anne, Hughes, Brett Gordon Maxwell, Wyld, David, Kennedy, Glen, Eastgate, Melissa A. and Lwin, Zarnie (2020). Psychosocial impacts of COVID-19 on oncology workforces: metro versus regional Australia. 2020 ASCO Quality Care Symposium, Chicago, IL USA, 9-10 October 2020. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2020.38.29_suppl.111 |
|
2020 Conference Publication Emotional impact of COVID-19 preparations on metro and regional cancer workforces in Queensland Australia: "We are all in this together"Roberts, Natasha Anne, Chan, Bryan, Ahern, Elizabeth Stephanie, Gasper, Harry Michael, Kennedy, Glen, Hughes, Brett Gordon Maxwell, Wyld, David, Eastgate, Melissa A. and Lwin, Zarnie (2020). Emotional impact of COVID-19 preparations on metro and regional cancer workforces in Queensland Australia: "We are all in this together". 2020 ASCO Quality Care Symposium, Chicago, IL USA, 9-10 October 2020. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2020.38.29_suppl.44 |
|
2019 Conference Publication Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+T cells (PD1tR) driven by tumour CD155de Oliveira, A. Lepletier, Madore, J., O'donnell, S., Johnston, R. L., Eastgate, M., Mallardo, D., Ascierto, P. A., Massi, D., Merelli, B., Mandala, M., Wilmott, J. S., Bald, T., Stagg, J., Routy, B., Long, G. V., Scolyer, R. A., Waddell, N., Dougall, W. C., Teng, M. W. L. and Smyth, M. (2019). Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+T cells (PD1tR) driven by tumour CD155. Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11-14 December 2019. Oxford, United Kingdom: Oxford University Press. |
|
2019 Conference Publication Royal Brisbane MedicalOncology Clinic Activity ReviewKuchel, Anna, Kermond, Anna, Lonton, Jennifer, Wyld, David and Eastgate, Melissa (2019). Royal Brisbane MedicalOncology Clinic Activity Review. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, SA Australia, 12–14 November 2019. Chichester, West Sussex United Kingdom: Wiley-Blackwell. |
|
2018 Conference Publication Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanomaEastgate, Melissa A., Atkinson, Victoria, Khattak, Muhammad Adnan, Roy, Amitesh Chandra, Haydon, Andrew Mark, Mueller, Christian, Dunkelmann, Tina, Brignone, Chrystelle and Frederic, Triebel (2018). Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2018.36.15_suppl.e15099 |
